Boston Scientific Corporation $BSX Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 7.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,828,010 shares of the medical equipment provider’s stock after purchasing an additional 196,498 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.19% of Boston Scientific worth $303,757,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. Sound Income Strategies LLC raised its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. 1248 Management LLC bought a new stake in shares of Boston Scientific in the 1st quarter worth about $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter valued at about $27,000. Princeton Global Asset Management LLC bought a new position in shares of Boston Scientific during the second quarter worth about $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Boston Scientific by 72.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 145 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 1.0%

Boston Scientific stock opened at $100.05 on Friday. The firm has a market capitalization of $148.26 billion, a P/E ratio of 53.50, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a 50-day simple moving average of $100.09 and a 200-day simple moving average of $102.45. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on BSX shares. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 24th. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. UBS Group raised their price target on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Wells Fargo & Company lifted their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $123.77.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 175,782 shares of company stock worth $17,742,314 over the last 90 days. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.